A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...
🛍️ Amazon Big Spring Sale: 100+ editor-approved deals worth buying right now 🛍️ By Amy Shira Teitel Published Apr 1, 2016 11:46 PM EDT Add Popular Science (opens in a new tab) Adding us as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results